Shares of Akari Therapeutics PLC (NASDAQ:AKTX) have been assigned an average broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and one has issued a strong buy rating on the company.
Brokers have set a one year consensus price objective of $2.50 for the company and are anticipating that the company will post ($1.00) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Akari Therapeutics an industry rank of 111 out of 265 based on the ratings given to related companies.
Several brokerages have recently weighed in on AKTX. Chardan Capital reaffirmed a “neutral” rating on shares of Akari Therapeutics in a research note on Sunday, September 17th. Zacks Investment Research raised Akari Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 23rd. ValuEngine raised Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 30th. William Blair raised Akari Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Friday, September 22nd. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $15.00 target price on shares of Akari Therapeutics in a research note on Friday, September 22nd.
Shares of Akari Therapeutics (AKTX) traded up $0.04 during mid-day trading on Thursday, hitting $4.17. The stock had a trading volume of 323,167 shares, compared to its average volume of 403,396. Akari Therapeutics has a twelve month low of $3.18 and a twelve month high of $22.20.
COPYRIGHT VIOLATION WARNING: “Brokerages Anticipate Akari Therapeutics PLC (AKTX) to Post ($1.00) Earnings Per Share” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://sportsperspectives.com/2017/12/17/brokerages-anticipate-akari-therapeutics-plc-aktx-to-post-1-00-earnings-per-share.html.
About Akari Therapeutics
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.